Immunohistochemistry

Today, prostate cancer is usually detected through screening, and there are two methods for early detection. The prostate-specific antigen test (PSA) is used, but there are

In the case for PSA screening, PCa is the leading internal malignancy in US men and the second leading cause of cancer death in American men. Early detection of prostate cancers offers the best chance of cure. The PSA blood test is the best chance of cure. Currently, the PSA blood test is the best currently available way to detect PCa and it is easy, safe and inexpensive. PSA test results is a piece of information, it is what doctors do with the information that becomes the issue. However, the great majority of PSA detected tumors have the histologic characteristics of clinically important cancers. Also, PSA detection has found tumors early advancing the diagnosis by Seeral years (5-13) and prostate cancer mortality rates in U.S have decreased by 4% (patho book) since 1992, which is 5 years after initiation of prostate screenings. The dilemma is over treating the clinically unimportant disease versus under

Another method to detect this cancer is with a Prostate Specific Antigen (PSA). Protein in the blood that is produced only by prostate cells is reflected the volume of both benign and malignant prostate tissue in the PSA. The higher the PSA level is the more likely it is that Prostate Cancer present. (“Prostate

Papanicolaou test fails to detect, on average, 50% of clinically significant pre-cancers and cancers that are present at the time of testing. The interpretation of Papanicolaou smears is subjective, and cellular abnormalities may be missed because of the reader's fatigue and distraction. Another drawback of the Papanicolaou test is the need for highly skilled cytotechnologists, the training of whom takes several years (Louvanto, Chevarie-Davis, Ramanakumar, Franco, & Ferenczy, 2014).

Each year approximately 233,000 men will be diagnosed with prostate cancer (Eggener, Cifu, & Nabhan, 2015). In 2015, prostate cancer was the second most common cancer related cause of death among United States men (Eggener, et. al., 2015). While the majority of prostate cancers are slow growing with a 5-year survival rate of approximately 98%, statistics show that when prostate cancer is identified as metastatic, the 5-year survival rate dramatically drops down to 20-25% (Eggener, et. al., 2015). According to these numbers alone, it appears screening for prostate cancer would be a well-accepted practice. However, current methods of screening for this cancer are controversial and has lead organizations like the U.S Preventative Service Task Force (USPSTF) and the American Cancer Society (ACS) to different guidelines for screening.

The paper Prostate Cancer Screening is written as an analysis of the controversy on the use of screening for prostate cancer. The paper itself is written between doctors Elie Mulhem, Nikolaus Fulbright, and Norah Duncan. The analysis, while likely directed to those in the medical field, is tailored to be easily understood by laypeople. While the paper itself is a somewhat brief, surface level analysis of the situation, it does support the notion that prostate cancer screening through methods like prostate-specific antigen (PSA) testing and digital-rectal examinations (DRE) have questionable effectiveness. The intention of the paper appears to persuade doctors and the public to the viewpoint that prostate

After all the different types of testing if there is any abnormality then a biopsy would be the next step. A prostate biopsy is a procedure in which the doctor uses the Trans rectal ultrasound (TRUS) to view and guide a needle into the prostate to take small samples of tissue. These tissues are then examined under a microscope for the presence of cancer. The biopsy procedure is short and you can usually go home the same day. There may be some

Prostate cancer is a kind of cancer that affects the prostate gland in men. It is a common cancer that grows slowly and its treatment can be done successfully if it is detected at an early stage. Sometimes, symptoms are not visible in case of cancer limited to the prostate gland which may result into metastatic cancer. To detect the symptoms, active surveillance can be done. There are various options available

Physicians can perform tests on DNA, RNA and cell proteins to determine if cancer is present within the body. After an individual discovers a sign that leads them to believe that cancerous cells are present within their body, an assessment of a biopsy is the most accurate and common procedure to determine the presence and type of cancer. A biopsy is a process in which a small sample of body tissue is removed and examined by an expert. These processes of detection lead to the declaration of cancer type and viable treatment plans.

Prostate cancer (PCa) is the commonest malignancy tumour in men and is second in cancer related death after lung cancer. PCa is mainly adenocarcinomas originating from the cortex of the gland (D’Elia et al. 2014).

This is a population based retrospective study. It examined the incidence of hospitalization among men who underwent TRUS guided prostates biopsy between January 1, 1996 and December 31, 2005 in Ontario Canada. No independent or dependent variables were identified. TRUS guided biopsies were carried out by relatively small number (437) of specialist physicians (urologists) (Nam et al., 2012). The researchers used Ontario Health Insurance Plan codes, Canadian

We recommend in later studies to use larger samples and compare the DWI ADC results to post-prostatectomy pathological results so we can correlate the results to accurate Gleason score and even detect central gland carcinoma pathologically to compare with DWI MRI results.

Tumour markers are detectable cancer cells that are found in the spinal fluid, urine or blood (Craft, Gordon & Tiziani, 2011). They can include enzymes, hormones, antigens or genes (Craft, Gordon & Tiziani, 2011).Tumour markers are beneficial, in that they are able to identify high risk cancers in individuals (Craft, Gordon & Tiziani, 2011). They also help by diagnosing different cancer types (Craft, Gordon & Tiziani, 2011).There are different markers that are able to identify different cancer types (Craft, Gordon & Tiziani, 2011). For example, Prostrate-specific antigen (PSA) identifies prostate cancer cells and a-fetoprotein (AFP) identifies Hepatic cancer cells (Craft, Gordon & Tiziani, 2011). There is a disadvantage of using tumour markers, and that is that some non-cancerous tissues produce markers (Craft, Gordon & Tiziani, 2011). Therefore, to determine whether a patient has cancer, additional tests are necessary (Craft, Gordon & Tiziani, 2011).

PLCO trial randomly assigned 76,685 men aged 55 to 74 years to annual PSA screening for 6 years (and concomitant digital rectal examination for 4 years) or to usual care (Adroile, Crawford, Grubb et al, 2012). It used a PSA cutoff of 4.0 μg/L. Diagnostic follow-up for positive screening test results and treatment choices were made by the participant and his personal physician; 90% of men with prostate cancer diagnoses received active treatment (surgery, radiation, hormonal therapy, or some combination(Adroile, Crawford, Grubb et al, 2012). After 7 years (complete follow-up), a nonstatistically significant trend toward increased prostate cancer mortality was seen in the screened group (RR, 1.14 [CI, 0.75 to 1.70]) compared with men in the control group (Andriole, Crawford Grubb et al., 2009).

There are times where specialists require some assistance in discovering the particular issues and states of their patients. At the point when specialists need to be certain about what their patients' conditions are, they take body liquid or tissue tests from them and forward these examples to the pathology advisors.